首页 | 本学科首页   官方微博 | 高级检索  
检索        

肺腺癌A549/DDP细胞多药耐药机制及中药逆转剂的研究进展
引用本文:刘小菊,刘红云,王海娟,张美芝,李宁,高杰.肺腺癌A549/DDP细胞多药耐药机制及中药逆转剂的研究进展[J].中国实验方剂学杂志,2015,21(21):227-230.
作者姓名:刘小菊  刘红云  王海娟  张美芝  李宁  高杰
作者单位:山东中医药大学 基础医学院, 济南 250355,山东电力中心医院, 济南 250300,山东中医药大学 基础医学院, 济南 250355,山东中医药大学 基础医学院, 济南 250355,山东中医药大学 基础医学院, 济南 250355,山东中医药大学 基础医学院, 济南 250355
基金项目:山东省自然科学基金青年基金项目(ZR2014HP022);山东中医药大学2013年“名科工程”青年骨干培养计划普通课题项目(ZYDXY1321)
摘    要:肺癌是严重影响人类生存的恶性肿瘤之一,其死亡率已居全球恶性肿瘤之首。目前主要采取以化疗为主的综合治疗方案,其疗效并不理想,主要原因是肺癌细胞对化疗药物产生多药耐药性(multi-drug resistance,MDR)。近年来肺腺癌耐药发生率高于鳞癌,应用cis-dichlorodiamineplatinum(DDP)诱导建立的肺腺癌多药耐药细胞系A549/DDP具有代表性。因此深入研究肺腺癌A549/DDP细胞的MDR机制及寻找安全、有效的逆转剂则成为当务之急。文献检索研究表明,肺腺癌A549/DDP细胞多药耐药机制主要涉及膜转运蛋白介导的药物外排泵机制、酶介导的肿瘤细胞解毒和修复功能增强、凋亡调控基因异常、信号转导因子发挥抗凋亡机制、上皮-间质细胞转化(EMT)导致的免疫逃逸。针对肺腺癌A549/DDP细胞多药耐药的中药逆转剂则主要涉及中药单体、中药复方、单味中药及中药有效成分、提取复合物。现就近年来肺腺癌A549/DDP细胞多药耐药机制及中药逆转剂的研究进展作一综述。

关 键 词:肺腺癌  A549/DDP细胞  多药耐药  中药  逆转
收稿时间:4/8/2015 12:00:00 AM

Research Progress of Lung Adenocarcinoma A549/DDP Cells Multi-drug Resistant Mechanism and Traditional Chinese Medicine Reversal Agents
LIU Xiao-ju,LIU Hong-yun,WANG Hai-juan,ZHANG Mei-zhi,LI Ning and GAO Jie.Research Progress of Lung Adenocarcinoma A549/DDP Cells Multi-drug Resistant Mechanism and Traditional Chinese Medicine Reversal Agents[J].China Journal of Experimental Traditional Medical Formulae,2015,21(21):227-230.
Authors:LIU Xiao-ju  LIU Hong-yun  WANG Hai-juan  ZHANG Mei-zhi  LI Ning and GAO Jie
Institution:Basic Medicine School, Shandong University of Traditional Chinese Medicine, Ji'nan 250355, China,Shandong Electric Power Central Hospital, Ji'nan 250300, China,Basic Medicine School, Shandong University of Traditional Chinese Medicine, Ji'nan 250355, China,Basic Medicine School, Shandong University of Traditional Chinese Medicine, Ji'nan 250355, China,Basic Medicine School, Shandong University of Traditional Chinese Medicine, Ji'nan 250355, China and Basic Medicine School, Shandong University of Traditional Chinese Medicine, Ji'nan 250355, China
Abstract:Lung cancer is one of the malignant tumors that seriously influence human survival. Its mortality rate has been among the top of the global malignant tumors. Comprehensive treatment scheme mainly with chemotherapy is generally adopted, but the curative effect is not ideal. The main reason is that the lung cancer cells produce multi-drug resistance (MDR) to chemotherapy drugs. The drug resistance incidence of lung adenocarcinoma in recent years is higher than that of squamous cell carcinomas. Multi-drug resistant cell line A549/DDP of lung adenocarcinoma induced by cis-Dichlorodiamineplatinum (DDP) is very representative. Therefore, further study of lung adenocarcinoma A549/DDP cells MDR mechanisms and looking for safe and effective reversal agents have become the urgent matter. Literature retrieval research has shown that lung adenocarcinoma A549/DDP cells multi-drug resistance mechanism mainly involves membrane transport protein-mediated drug efflux pump mechanism, enzyme-mediated tumor cells detoxification and repair enhancements, abnormal apoptosis regulation genes, antiapoptotic mechanism of signal transduction factors and immune escape caused by Epithelial-Mesenchymal transit (EMT). Reversal agents of traditional Chinese medicines aiming at lung adenocarcinoma A549/DDP cells multi-drug resistance are mainly related to traditional Chinese medicine monomer, traditional Chinese medicine compound, single Chinese medicine and its effective components, and extraction of compounds. Here we will further review lung adenocarcinoma A549/DDP cells multi-drug resistant mechanism and research progress of reversal agents in traditional Chinese medicine.
Keywords:lung adenocarcinoma  A549/DDP cells  multi-drug resistant  traditional Chinese medicine  reverse
本文献已被 CNKI 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号